Introduction
Materials and methods
Patients
Variable | This study | Data from [7] | Pvalue |
---|---|---|---|
Age in years, mean ± SD | 54.2 ± 13.1 | 57 ± 13.5 | 0.06 |
Age in years at diagnosis, mean ± SD | 46.2 ± 13.5 | 47 ± 15 | 0.3 |
Women, percentage | 84.8 | 75 | 0.06 |
Disease duration in years, mean ± SD | 7.8 ± 6.6 | 8 ± 8 | 0.4 |
Current smokers, percentagea | 9.1 | 15 | 0.3 |
Ever smokers, percentagea | 25.0 | ||
Rheumatoid factor-positive, percentage | 68.9 | 83.8 | 0.01 |
Anti-CCP-positive, percentagea | 86.3 | 61.9 | 0.0001 |
Shared epitope-positive, percentagea | 58.3 | ||
Antinuclear antibody-positive, percentagea | 29.8 | ||
HAQ at baseline, mean ± SD | 1.4 ± 0.7 | 1.1 ± 0.6 | 0.0005 |
DAS28 at baseline, mean ± SD | 5.6 ± 1.2 | 5.2 ± 0.8 | 0.002 |
DAS28 ≥ 5.1, percentage | 70.2 | ||
3.2 ≤ DAS28 > 5.1, percentage | 26.5 | ||
DAS28 at 12 to 16 weeks, mean ± SD | 3.6 ± 1.4 | 3.7 ± 1.3 | 0.2 |
DAS28 at 6 months, mean ± SD | 3.5 ± 1.4 | ||
Good responders at 12 to 16 weeks, percentage | 40.4 | 34.8 | 0.6 |
Non-responders at 12 to 16 weeks, percentage | 22.5 | 25.8 | 0.6 |
Good responders at 6 months, percentage | 43.7 | ||
Non-responders at 6 months, percentage | 21.8 | ||
Anti-tumor necrosis factor drug | |||
Infliximab, number | 101 | 32 | 0.01 |
Etanercept, number | 35 | 39 | 0.02 |
Adalimumab, number | 15 | 18 | 0.05 |
Assessment of the efficacy of the treatment
Genotypes
Single-nucleotide polymorphisms | Pvalue of relDAS28 | MAF of responders, percentage (n/N) | MAF of non-responders, percentage (n/N) | ORa(95% CI) | Pvalue |
---|---|---|---|---|---|
rs983332 | 0.6 | 25.9 (30/116) | 27.9 (19/68) | 1.11 (0.6-2.0) | 0.8 |
rs928655 | 0.1 | 18.9 (23/122) | 28.0 (19/68) | 0.60 (0.3-1.2) | 0.1 |
rs13393173 | 0.8 | 23.8 (29/122) | 20.6 (14/68) | 0.83 (0.4-1.7) | 0.6 |
rs437943 | 0.05 | 38.5 (47/122) | 25.0 (17/68) | 0.53 (0.3-1.0) | 0.06 |
rs10945919 | 0.7 | 27.9 (34/122) | 23.5 (16/68) | 0.79 (0.4-1.7) | 0.5 |
rs854547 | 0.3 | 39.3 (48/122) | 36.8 (25/68) | 1.12 (0.6-2.1) | 0.7 |
rs854548 | 0.9 | 23.0 (28/122) | 23.5 (16/68) | 1.03 (0.5-2.0) | 0.9 |
rs854555 | 0.6 | 35.2 (43/122) | 38.2 (26/68) | 1.14 (0.6-2.0) | 0.7 |
rs868856 | 0.6 | 32.8 (40/122) | 36.8 (25/68) | 1.19 (0.6-2.0) | 0.6 |
rs7046653 | 0.5 | 32.0 (39/122) | 36.8 (25/68) | 1.23 (0.7-2.5) | 0.5 |
rs2814707 | 0.8 | 25.4 (31/122) | 29.4 (20/68) | 1.22 (0.6-2.5) | 0.6 |
rs3849942 | 0.4 | 23.0 (28/122) | 29.4 (20/68) | 1.41 (0.7-2.5) | 0.3 |
rs774359 | 0.2 | 26.2 (32/122) | 36.8 (25/68) | 1.64 (0.8-3.3) | 0.1 |
rs6138150 | 0.5 | 14.0 (17/122) | 14.7 (10/68) | 0.94 (0.4-2.2) | 0.9 |
rs6028945 | 0.9 | 12.3 (15/122) | 13.2 (9/68) | 1.09 (0.5-2.5) | 0.9 |
rs6071980 | 0.9 | 18.9 (23/122) | 16.2 (11/68) | 0.83 (0.4-2.0) | 0.6 |